SAN DIEGO and PENNINGTON, N.J., Nov. 6, 2018 /PRNewswire/ — OncoSec Medical Incorporated (OncoSec) (NASDAQ: ONCS), a company developing novel cancer immunotherapies based on its proprietary technology generating sustained intratumoral IL-12 levels, today reported preliminary data from KEYNOTE-695, a global, multicenter Phase 2b, open-label trial of intratumoral delivery of TAVO™ (tavokinogene telseplasmid / IL-12) with intravenous …
Tag Archives: metastatic melanoma
November, 2018
September, 2017
-
27 September
OncoSec Presents Data on the Ability of the Combination of ImmunoPulse IL-12 and Pembrolizumab to Convert “Cold” to “Hot” Tumors
SAN DIEGO, Sept. 27, 2017 /PRNewswire/ — OncoSec Medical Incorporated (“OncoSec”) (NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, today presented an overview of the comprehensive immune monitoring data from the Phase 2 Investigator Sponsored Trial led by the University of California, San Francisco (UCSF) at the 2nd World …
June, 2017
-
9 June
OncoSec’s Investigational Melanoma Drug Receives Orphan Drug Designation from the FDA
SAN DIEGO, June 8, 2017 /PRNewswire/ — OncoSec Medical Incorporated (“OncoSec”) (NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for pIL-12, otherwise known as tavokinogene telsaplasmid, for the treatment of unresectable metastatic melanoma. Tavokinogene …
February, 2017
-
27 February
FDA Grants Fast Track Status to OncoSec’s ImmunoPulse IL-12 for the Treatment of Metastatic Melanoma
SAN DIEGO, Feb. 27, 2017 /PRNewswire/ — OncoSec Medical Incorporated (“OncoSec”) (NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, received Fast Track designation from the U.S. Food and Drug Administration (FDA) for its ImmunoPulse® IL-12, a potentially first-in-class, Intratumoral anti-cancer gene therapy that expresses interleukin-12 (IL-12) for the treatment …
January, 2016
-
25 January
FDA Expands Approval of BMS’ Opdivo in Combination with Yervoy for Certain Melanoma Patients
PRINCETON, N.J.–(BUSINESS WIRE)–Bristol-Myers Squibb Company (NYSE:BMY) today announced that the U.S. Food and Drug Administration (FDA) has approved Opdivo (nivolumab) in combination with Yervoy (ipilimumab) for the treatment of patients with BRAF V600 wild-type and BRAF V600 mutation-positive unresectable or metastatic melanoma.1 This indication is approved under accelerated approval based on progression-free …
November, 2015
-
23 November
Roche’s Melanoma Drug Performs Well in Early-Stage Study
Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced data from the pivotal coBRIM study, which showed that Cotellic (cobimetinib) in combination with Zelboraf (vemurafenib) helped people with BRAF V600E and V600K mutation-positive unresectable or metastatic melanoma live significantly longer (overall survival; OS) than with Zelboraf alone.1 Cotellic plus Zelboraf reduced …